Although widespread travel and the internet have made the world a much ‘smaller’ place there have still been differences in the way we report the histopathology of cancers across the world. Most of these differences have been minor but some have been significant and have made comparative studies, e.g. prognosis related to stage, difficult. Recently the International Collaboration on Cancer Reporting (ICCR) has set up a number of working groups to produce standardised datasets for cancer in different organ systems. The latest dataset, on ovary, fallopian tube and primary peritoneal carcinoma, has just been published in Modern Pathology. With contributors from the UK, Australia, Canada, Norway, the Netherlands, Spain, Japan and the USA there is a wide geographical distribution and they have produced a well-designed evidence-based dataset.
Lymphangioleiomyomatosis (LAM) has always fascinated me since I saw a case as a young trainee pathologist. Was an apparently benign tumour of smooth muscle in the uterus (as it was in that case) really ‘metastasising’ in lymphovascular channels? Our knowledge of this condition has moved on since then and we now know it to be often found in patients with pulmonary lymphangiomyomatosis, the tuberous sclerosis complex and other vascular neoplasms. Rabban et al. have published an excellent clinicopathological study in this month’s American Journal of Surgical Pathology which looks at clinically occult LAM in pelvic lymph nodes removed for tumours of the uterus, ovary, cervical or bladder. They found 26 cases – none had pulmonary LAM and only 2 had tuberose sclerosis complex. This shows that clinically-occult LAM is still largely a condition which doesn’t have any particular associations with other disease complexes and its pathogenesis is still obscure.